Summary & Overview
HCPCS Level II J0638: Canakinumab Injection, 1 mg
HCPCS Level II code J0638 denotes the supply of canakinumab measured per 1 mg and is used when reporting the injectable biologic on medical claims. Canakinumab is a monoclonal antibody used for certain inflammatory and autoinflammatory conditions, and accurate coding for dosage units is important for clinical documentation, billing consistency, and national spend tracking.
Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how the code is used in outpatient and office-based settings, benchmarks for unit reporting and claim line handling, and the clinical context for canakinumab administration. The publication also covers common billing practices, relevant modifiers and reporting nuances, and considerations for claim adjudication across major national payers.
This summary is intended to inform billing staff, practice managers, and policy analysts about the role of J0638 in medical claims, what to expect in payer coverage patterns, and where to look for policy updates affecting injectable biologics.
Billing Code Overview
HCPCS Level II code J0638 represents Injection, canakinumab, 1 mg. This code is used to report the administration or supply of canakinumab in 1 mg increments for systemic therapy.
Service Type: Drug administration / injectable biologic
Typical Site of Service: Outpatient clinic, infusion center, or physician office
Data not available in the input for associated taxonomies, ICD-10 diagnoses, or related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a documented autoinflammatory condition such as familial Mediterranean fever or periodic fever syndromes, or a patient with refractory gout or adult-onset Still disease, requiring targeted interleukin-1 beta inhibition. The medication J0638 (canakinumab, 1 mg per unit) is provided as a subcutaneous injection prepared by clinic nursing staff from vials or prefilled syringes and administered in an outpatient infusion/injection suite, specialty clinic, or physician office. The clinical workflow includes verification of indication and prior authorization, documentation of baseline vitals and review for active infection, preparation of the correct dose based on weight or protocol, administration by a licensed nurse, observation for immediate adverse reactions (typically 15–60 minutes depending on patient risk), and documentation of lot number, dose, route, site, and any patient counseling. Billing for J0638 is per milligram units; the number of units reported must match the exact milligrams administered. Typical payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare, each following their medical necessity and coverage policies for biologic agents.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered |